Can-Fite Biopharma Profit Margin

The latest profit margin for CANF is -2426.67% as of December 2025. That compares with -1168.99% in the prior-year period — down 107.6% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Can-Fite Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, CANF's profit margin moved from -1168.99% to -2426.67% — a 107.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Can-Fite Biopharma's valuation or profitability profile.

Against Healthcare companies, CANF currently prints -2426.67% for profit margin, while the sector average sits near 13.89%. That is roughly 17566.7% below the sector mean. Large gaps often invite a closer look at Can-Fite Biopharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Can-Fite Biopharma converts resources into returns. At -2426.67%, CANF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1168.99% in the prior-year period — down 107.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CANF's profit margin (-2426.67%), review year-over-year change from -1168.99%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.